Vonoprazan/amoxicillin
Combination medication
From Wikipedia, the free encyclopedia
Vonoprazan/amoxicillin, sold under the brand name Voquezna Dual Pak among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[1] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker and amoxicillin, a beta-lactam antibiotic.[1] It is taken by mouth.[1]
| |
| Combination of | |
|---|---|
| Vonoprazan | Potassium-competitive acid blocker |
| Amoxicillin | Beta-lactam antibiotic |
| Clinical data | |
| Trade names | Voquezna Dual Pak |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
The co-packaged medication was approved for medical use in the United States in May 2022.[1][2][3][4]
Medical uses
Research
The dual therapy of using vonoprazan with amoxicillin has been investigated for the treatment of H. pylori infection[6] and also compared with the triple therapy of using vonoprazan, amoxicillin, and clarithromycin for the eradication of H. pylori infection.[7] Both treatments have been found to be effective.[6][7] As of 2024,[update] evidence indicates that vonoprazan/amoxicillin therapy has similar efficacy to bismuth-containing quadruple therapies in eliminating H. pylori.[8]
